Puluo Pharmaceutical Co., Ltd. and Shanghai Institute of Pharmaceutical Research Co., Ltd. to develop 1.1 new chemical drugs

Puluo Pharmaceutical (000739) announced in the evening of June 8 that in order to promote the company's business from APIs to pharmaceutical products, and then to innovative drugs, Zhejiang Jutai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, signed a technology development contract with Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences on the new drugs yg-001 and yg-056sp of chemical 1.1 Jutai pharmaceutical has a total investment of 70 million yuan Among them, yg-001 is a new FXa inhibitor (Saban) anticoagulant candidate drug developed by Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences, which has independent intellectual property rights at home and abroad Yg-056sp is a new type of oxazolidinone anti multidrug resistant bacteria (super antibiotic) candidate drug with international and domestic independent intellectual property rights developed by Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences The project is a major special plan for new drug development in China PLO pharmaceutical said that the cooperation will help to make better use of the advantages of external higher research institutions and enterprises in human resources, scientific research, industrialization and commercialization Jutai pharmaceutical has transferred the technical achievements of Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences, and can systematically carry out clinical research on new drugs If there is no termination event, the completion of the project is expected to take 5-6 years Appendix: Puluo pharmaceutical: announcement of the board of directors on the cooperation between the company's subsidiary and Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences on the development of new drugs securities code: 000739 securities abbreviation: Puluo pharmaceutical Announcement No.: 2015-33 announcement of the board of directors of Puluo Pharmaceutical Co., Ltd on the cooperation between the company's subsidiary and Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences on the development of new drugs The company and all members of the board of directors guarantee that the content of information disclosure is true, accurate and complete, and there is no false record, misleading statement or major omission 1、 Based on the product development strategy of "combination of imitation and innovation" adopted by the company in the development of preparation business, in order to promote the company's business from API to preparation, and then to innovative drugs, recently, Zhejiang Jutai Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhejiang Pradesh Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, and China Science The Institute of Shanghai Pharmaceutical Research signed a "technology development contract" for yg-001 and yg-056sp, a new chemical drug of category 1.1 The technology development contract stipulates that payment shall be made according to the development milestones of the project, and risk sharing and benefit sharing shall be implemented Yg-001 is a new type of FXa inhibitor (Saban) anticoagulant candidate drug developed by Shanghai Institute of medicine, Chinese Academy of Sciences, which has independent intellectual property rights at home and abroad Yg-056sp is a new type of oxazolidinone anti multidrug resistant bacteria (super antibiotic) candidate drug with international and domestic independent intellectual property rights developed by Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences The project is a major special plan for new drug development in China The cooperation of the project is in line with the company's development strategy 2、 Main situation of cooperation (I) this cooperation mainly involves the technical development of yg-001 and yg-056sp projects (entrusted cooperative development) （2） Zhejiang Jutai Pharmaceutical Co., Ltd has a total investment of 70 million yuan (including 40 million yuan of research and development funds for new drug yg-001 project and 30 million yuan of research and development funds for new drug yg-056sp project) Zhejiang Jutai Pharmaceutical Co., Ltd is responsible for the financing 3、 The main content of the agreement is as follows: Party A: Zhejiang Jutai Pharmaceutical Co., Ltd (hereinafter referred to as "Jutai pharmaceutical") and Party B: Shanghai Institute of pharmaceutical research, Chinese Academy of Sciences (I) Both parties confirm that Party A shall pay the R & D funds and income distribution of the contract in the following ways, with the payment in installments as follows: 1 Within 15 working days after the signing of the contract, Party A shall pay the first amount of funds (1.0% of the total amount of research and development funds) 2 After the completion of the relevant verification test, Party A has no negative results hindering the realization of the technical objectives, and this contract will come into effect automatically Party A shall pay Party B 4.0% of the total research and development funds of this project within 15 working days after the completion of the test evaluation 3 After the pre clinical research is completed, Party A shall pay Party B 8.0% of the total amount of research and development funds of the project after receiving the acceptance number of CFDA (China food and Drug Administration) or foreign regulatory agency's clinical research application (the same below) 4 Party A shall pay Party B 5.0% of the total research and development funds of the project within one week after obtaining the phase I clinical approval from CFDA or foreign regulatory authority 5 Complete the phase I clinical research approved by CFDA or foreign regulatory agencies, and obtain the phase I clinical research summary report, without any negative results hindering the progress of the project Party A shall pay Party B 10.0% of the total research and development funds of the project within one week 6 Complete the phase II clinical research of CFDA or foreign regulatory agencies, and obtain the phase II clinical research summary report, without any negative results hindering the progress of the project Party A shall pay Party B 12% of the total research and development funds of the project within one week 7 Complete the phase III clinical research of CFDA or foreign regulatory agencies, and obtain the phase III clinical research summary report No negative results affecting the acquisition of new drug certificate are found Party A shall pay Party B 20% of the total research and development funds of the project within one week 8 Party A shall pay Party B 40% of the total research and development funds of the project within one week after obtaining the new drug certificate and production approval through CFDA or foreign regulatory agency review In each stage, Party A has the right to terminate the contract in case of any negative result hindering the progress of the project （2） Income distribution: after listing, Party A shall pay Party B 4.0% of the product sales (including various raw materials and preparations) The sales commission shall be calculated based on the ex factory price (excluding tax) of Party A, and the withdrawal period shall be limited to the patent period (or the new drug monitoring period, whichever is longer) Party A shall pay Party B one-time sales commission of the previous year in the third month of the next year after the end of each financial year （3） Intellectual property clause: the patent application right belongs to Party B (Party B has completed the domestic and international patent application), and the domestic patent maintenance fee shall be borne by Party B when Party A pays Party B more than 8 million yuan for the new drug yg-001 project (when Party A pays Party B more than 6 million yuan for the new drug yg-056sp project), the domestic patent shall be jointly owned by both parties, Party B shall add Party A as the patentee within 5 days after receiving the stipulated contract payment After Party A has paid RMB 40 million for the new drug yg-001 project (after Party A has paid RMB 30 million for the new drug yg-056sp project), Party A is the full owner of the domestic patent, and Party B can have the right of signature, and Party A shall bear all the patent maintenance fees thereafter International Patent: within 5 days after Party A pays 50% of the patent application fee, Party B shall add Party A as the joint owner of the international patent 4、 In order to make better use of the advantages of external higher research institutions and enterprises in human resources, scientific research, industrialization and commercialization, Zhejiang Jutai Pharmaceutical Co., Ltd started from the company's strategy, combined with the company's advantages in technology, market, resources, etc It is expected to take 5-6 years to complete the project if there is no termination event The project is in line with the company's future development strategy 5、 Special risks indicate that the development of a new drug, from the screened compounds to the final new drug listing, is a complex and long-term system engineering, with certain risks The company will carefully promote the development of the project under the condition of controlling risks as much as possible Please pay attention to the investment risk! It is hereby announced Board of directors of pulo Pharmaceutical Co., Ltd June 8, 2015